期刊文献+

SOCS-3和3-OST-2基因甲基化在子宫内膜癌中的作用及其临床病理意义

Effect of the methylation of SOCS-3 and 3-OST-2 genes in endometrial cancer and its clinical pathological significances
原文传递
导出
摘要 目的研究子宫内膜癌(EC)中相关抑癌基因(SOCS-1、SOCS-3、3-OST-2、DLC-1)的启动子甲基化状态,探讨其临床病理意义。方法收集60例EC、79例增生子宫内膜和27例正常子宫内膜标本,运用甲基化特异性PCR(MSP)技术检测4个抑癌基因的甲基化状态;MSP和实时荧光定量PCR法检测表观遗传学药物处理前后Ishikaw a细胞株中抑癌基因甲基化及mRNA表达变化。结果在EC中,SOCS-1和DLC-1基因甲基化率较低(分别为13.3%和21.7%),SOCS-3和3-OST-2基因甲基化率很高(分别为88.3%和78.3%),且SOCS-3在复杂和不典型增生中就出现高频率的甲基化(分别为53.3%和54.2%)。3-OST-2甲基化与肿瘤分化呈正相关(P<0.05)。SOCS-3和3-OST-2在Ishikaw a细胞株中均呈完全甲基化状态,DNA甲基转移酶(DNMT)抑制剂5-Aza-dC或组蛋白去乙酰化酶(HDAC)抑制剂TSA处理后甲基化均得到部分逆转,mRNA表达明显增加,且TSA效果优于5-Aza-dC;两药联合处理后甲基化被完全逆转,mRNA水平显著升高。结论 SOCS-3、3-OST-2基因启动子甲基化在EC中是一个频发事件,且SOCS-3甲基化的发生早于3-OST-2。DNA甲基化和组蛋白修饰共同参与了3-OST-2和SOCS-3的基因表达调控,并存在交叉作用。 Objective To analyze the promoter methylation status of multiple tumor suppressor genes (TSGs) (SOCS-1, SOCS-3, 3-OST-2, DLC-1) in endometrial carcinoma (EC) and explore its clinical pathological significances. Methods Sixty EC samples, 79 hyperplasia endometrium and 27 normal endometrium were collected. We performed methylation specific PCR (MSP) to detect the promoter methylation of the TSGs. The changes of DNA methylation and gene expression before and after the treatment of epigenetic drugs in Ishikawa cells were investigated by MSP and Real-time PCR, respectively. ResultsIn EC, the methylation rate of SOCS-1 and DLC-1 genes was low(13.3% and 21.7%, respectively), and that of SOCS-3 and 3-OST-2 genes was very high (88.3% and 78.3%, respectively). High frequency of SOCS-3 methylation was also found in complex hyperplasia and atypical hyperplasia (53.3% and 54.2%, respectively). 3-OST-2 was positively correlated with tumor differentiation (P〈0.05). Both SOCS-3 and 3-OST-2 complete methylation were detected in untreated Ishikawa cells and were partially reversed by 5-Aza-dC or TSA. Expression of mRNA increased and TSA was more efficient than 5-Aza-dC in inducing the gene expression. After treatment by the combination of the two inhibitors, SOCS-3 and 3-OST-2 methylation was completely reversed and mRNA SOCS-3 and 3-OST-2 significantly increased. Conclusions SOCS-3 and 3-OST-2 promoter methvlaion is an early and frequent event in EC and the methylation of SOCS-3 occurred earlier than that of 3-OST-2. DNA methylation and histone modifications contribute to the transcriptional regulation of SOCS-3 and 3-OST-2, and there is a cross-talk between them.
出处 《山东大学学报(医学版)》 CAS 北大核心 2013年第6期75-80,共6页 Journal of Shandong University:Health Sciences
基金 国家自然科学基金(81272277)
关键词 子宫内膜肿瘤 抑癌基因 DNA甲基化 表观遗传 Endometrial neoplasms Tumor suppressor gene DNA methylation Epigenetic
  • 相关文献

参考文献20

  • 1Fu L, Dong S S, Xie Y W, et al. Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma[J]. Hepatology, 2010, 5l (5) : 1624-1634.
  • 2张银丽,郭小荣,沈丹华,成夜霞,梁旭东,陈云新,王颖.p73基因在卵巢上皮性肿瘤中的表达及甲基化研究[J].中华病理学杂志,2012,41(1):33-38. 被引量:2
  • 3Salvesen H B, Stefansson I, Kretzschmar E I, et al. Sig- nificance of PTEN alterations in endometrial carcinoma) a population-based study of mutations, promoter methyla- tion and PTEN protein expression[J]. Int J Oncol, 2004, 25(6) :1615-1623.
  • 4Nishimura M, Saito T, Yamasaki H, et al. Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells[J]. Carcinogenesis, 2003,24 (10) :1615-1623.
  • 5Guida M, Sanguedolce F, Bufo P, et al. Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/pl6 genes in benign, premalignant and malignant endometrial lesions [J ]. Eur J Gynaecol Oncol, 2009, 30(3 ) :267-270.
  • 6秦伟,李伶理,陆惠娜,黄滨滨,修冰,薄兰君,高清梅,张文君,傅建非.SOCS超甲基化与经典型慢性骨髓增殖性肿瘤的研究[J].中华血液学杂志,2011,32(11):772-776. 被引量:1
  • 7Weber A, Hengge U R, Bardenheuer W, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions andcanses growth inhi- bition [J ]. Oncogene, 2005, 24 (44) :6699-6708.
  • 8Furuta J, Umebayashi Y, Miyamoto K, et al. Promoter methylation profiling of 30 genes in human malignant melanoma(J]. Cancer Sci, 2004, 95(12) :962-968.
  • 9Miyamoto K, Asada K, Fukutomi T, et al. Methylation- associated silencing of heparin sulfate D- glucosaminyl 3- O-sulfotransferase-2 ( 3-OST-2 ) in human breast, colon, lung and pancreatic cancers [ J ]. Oncogene, 2003, 22 (2) :274-280.
  • 10Kim T Y, Jong H S, Song S H, et al. Transcriptional silencing of the DLC-1 tumor suppressor gene by epige- netic mechanism in gastric cancer cells [J ]. Oncogene, 2003, 22 ( 25 ) : 3943-3951.

二级参考文献31

  • 1朱栋元,马廷行.p73基因研究进展[J].肿瘤防治杂志,2005,12(24):1909-1912. 被引量:2
  • 2Usenko T, Eskinazi D, Correa PN, et al. Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF- I hypersensitivity of primary polycythemia vera (PV) cells. Leuk Lymphoma, 2007, 48 : 134-146.
  • 3Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer, 2008, 123 : 1586-1592.
  • 4Capello D, Deambrogi C, Rossi D, et al. Epigenetic inactivation of suppressors of cytokine signaling in Philadelphia-negative chro- nic myeloproliferative disorders. Br J Haematol, 2008, 141:504- 511.
  • 5Yhim HY, Kim HS, Sohn JY, et al. JAK2 V617F-positive es- sential thrombocythemia in a patient with Klineteher syndrome: a case report. Cancer Genet Cytogenet, 2010, 198:162-165.
  • 6Olcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferativc neoplasms. Nat Genet, 2009,41: 450-454.
  • 7Kralovics R, Teo SS, Buser AS,et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood, 2005, 106: 3374-3376.
  • 8Starr R, Willson TA, Viney EM, et al. A family of cytokine-induc- ible inhibitors of signaling. Nature, 1997,387:917-921.
  • 9Larsen L, Ropke C. Suppressors of cytokine signaling: SOCS. AP- MIS ,2002,110:833-844.
  • 10Haan S, Wtiller S, Kaczor J, et al. SOCS-mediated down regula- tion of mutant Jak2 (V617F, T875N and K539L) counteracts cy- tokine-independent signahng. Oncogene, 2009, 34:3069-3080.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部